Article
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Journal of cellular and molecular medicine - 1 Feb 2020
Weisberg Ellen, Meng Chengcheng, Case Abigail E, Tiv Hong L, Gokhale Prafulla C, Toure Anthia A, Buhrlage Sara, Liu Xiaoxi, Wang Jinhua, Gray Nathanael, Stone Richard, Adamia Sophia, Winer Eric, Sattler Martin, Griffin James D
Abstract excerpt
Mutations in the E3 ubiquitin ligase CBL, found in several myeloid neoplasms, lead to decreased ubiquitin ligase activity. In murine systems, these mutations are associated with cytokine-independent proliferation, thought to result from the activation of hematopoietic growth receptors, including FLT3 and KIT. Using cell lines and primary patient cells, we compared the activity of a panel of FLT3 inhibitors...
Topics
- Animals
- Cell Line, Tumor
- Humans
- Leukemia, Myeloid
- Mice
- Mutation
- Proto-Oncogene Proteins c-cbl
- Signal Transduction
- Staurosporine
- Syk Kinase